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INTRODUCTION:
Since the pulmonary veins (PVs) were first identified as the primary sources of initiating triggers of paroxysmal atrial fibrillation (AF) (1) , catheter ablation to achieve pulmonary vein isolation (PVI) has become the cornerstone of AF ablation (2) . Even in more persistent forms of AF, additional atrial ablation does not improve outcomes over PVI alone (3, 4) . However, 5 creating durable PVI is difficult to achieve, with contemporary studies demonstrating that up to two-thirds of patients after a successful PVI procedure have PV reconnection at protocolmandated repeat electrophysiology study (5, 6) . PV reconnection is well-recognized as the leading cause of atrial tachyarrhythmia (AT) recurrence following PVI (7) (8) (9) (10) , which occurs in around 30-40% of patients after a single procedure (11-13). Such AT recurrences 10 significantly impact upon quality-of-life (14, 15) .
Currently, patients re-presenting with AT recurrence commonly undergo repeat ablation, and this has been show to increase success rates (8) . However, there can be a significant delay between symptomatic recurrence and the second procedure, during which time quality-of-life can suffer. While clinical success rates have remained relatively static, the 15 safety of AF ablation has improved significantly over recent years (16, 17) . Given the high rates of late PV reconnection still seen, we designed the Pulmonary vein RE-isolation as a routine Strategy: a SUccess Rate Evaluation (PRESSURE) study to test the hypothesis that a strategy of assessment and re-isolation of all PV reconnection two months after the initial AF ablation, irrespective of symptoms, would reduce AT recurrence and improve quality-of-life.
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METHODS: Patient population:
Consecutive patients were recruited from a single tertiary center in the UK. Study inclusion criteria were as follows: a current pattern of paroxysmal AF (defined as ECG-proven episodes of AF which are self-limiting and last less than 7 days on each occasion, or which were cardioverted electrically or pharmacologically less than 48 hours from onset), aged over 18 years and scheduled for catheter ablation using radiofrequency energy. Exclusion criteria were: previous ablation procedure for AF, prosthetic mitral valve replacement, severe structural cardiac abnormality, infiltrative cardiomyopathy, severe left ventricular systolic 5 dysfunction (ejection fraction <35%) and pregnancy. All patients provided written informed consent and the study was approved by the UK National Research Ethics Service and the Institutional Research Committee.
Patients were enrolled prior to their initial ablation but randomization was delayed until immediately after the procedure in order to avoid possible bias or influence on the ablation.
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Randomization was in a 1:1 ratio using a custom-written two-and four-block randomization program to either Standard Care (SC) or to undergo a repeat electrophysiology study after 2 months, irrespective of symptoms (Repeat Study (RS) group). Due to the nature of the study design, randomization was blinded to neither patient nor clinician but all study analyses were performed by blinded observers. A diagram defining study time-periods is shown in Figure 1 .
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Initial PVI procedure:
Patients taking amiodarone had this stopped a minimum of 2 months prior to their PVI procedure; if this was not possible, the patient was excluded. All other anti-arrhythmic drugs were stopped 5 days prior. Patients taking warfarin continued this peri-procedurally, with an INR level of 2.0-3.5 considered acceptable. Non-Vitamin K anticoagulants were stopped 48 hours pre-procedure.
PVI was performed under conscious sedation with fentanyl and midazolam or general anesthesia in a standard fashion. Vascular access was gained under direct ultrasound guidance, as is standard in our institution (18) . A 3-dimensional navigation system (CARTO 3, Biosense Webster, Inc., Diamond Bar, CA) was used in all cases to create an electroanatomical map of the left atrium and, where possible, this was integrated with a computed tomography or magnetic resonance imaging reconstruction of the left atrium (CartoMerge, Biosense Webster, Inc.). PVI was performed in a wide area circumferential ablation (WACA) pattern using a 3.5mm irrigated tip contact force-sensing RF ablation Automated lesion tagging (VisiTag, Biosense Webster, Inc.) was used to mark the location of each lesion, using standardized settings as follows: Catheter Position Stability -Minimum 10 time 10sec, Maximum range 2mm; Force Over Time -Time 30%, Minimum force 5g; Lesion tag size -2mm. Contiguous lesions around the WACA circle were aimed for. Cavotricuspid isthmus ablation was permitted in patients with documented typical right atrial flutter, but no additional left atrial ablation was performed and no attempt was made to look for extra-PV triggers. AF that persisted after PVI was terminated with electrical cardioversion.
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Acute PVI was confirmed by demonstrating entry and exit block with a 20-pole circular mapping catheter (Lasso NAV Eco, Biosense Webster, Inc.) placed sequentially in each of the PVs. On-going PVI was confirmed a minimum of 20 minutes after isolation of that ipsilateral PV pair, with intravenous adenosine boluses (12-18mg) administered to unmask sites of dormant conduction. Further ablation was performed at sites of overt or unmasked 20 reconnection to re-isolate the PVs.
Post-procedure anti-arrhythmic drug therapy:
Pre-procedure anti-arrhythmic medications, including beta-blockers and rate-limiting calcium channel-blockers were restarted post-procedure and stopped after 4 weeks. Subsequent re-initiation of therapy was permitted by the attending physician to treat clinical arrhythmia recurrences, but was stopped again at the end of the 3-month blanking period.
Repeat Study group:
Repeat electrophysiology study was performed 2 months after the initial procedure in all patients in the RS group. Any re-initiated antiarrhythmic medications were stopped again 5 5 days prior. The repeat study was performed using 3-dimensional mapping in the same way as for the initial procedure. Each PV was assessed for reconnection using a 20-pole circular catheter. All identified sites of reconnection were ablated to re-isolate the PVs. As for the initial procedure, no additional left atrial ablation beyond PVI was performed. As prespecified, a data monitoring and safety committee review was held after half of the repeat 10 procedures in the RS group had been performed.
Standard Care group:
Patients in the SC arm did not undergo routine repeat electrophysiology study and, as per international guidelines, repeat ablation was not performed within the first three months (2).
Management was otherwise identical to the RS group, with options of anti-arrhythmic drugs 15 or repeat ablation available as per standard clinical care for patients with symptomatic AT after the 3-month blanking period.
ECG follow-up:
All patients were provided with a validated portable ECG monitor (Omron HCG-801-E, Omron Healthcare, Kyoto, Japan) (19) , and, having been trained in its use, were instructed to 20 self-record a 30-second ECG every day and additionally whenever they experienced symptoms. ECG recordings were downloaded at each follow-up visit and were analyzed for the presence and dates of any AT by experienced clinicians (YS, SG) blinded to treatment allocation.
Patient follow-up:
Follow-up visits were arranged after 6 weeks and 3, 6 and 12 months. Any anti-arrhythmic medications restarted for symptomatic documented AT during the blanking period were stopped again 3 months post-initial ablation. The validated AFEQT quality-of-life questionnaire, which involves 20 questions across 3 domains (symptoms, daily activities and 5 treatment concerns) using a 7-point Likert scale, was completed at baseline and at 6 and 12 months (20).
Study outcomes:
The primary outcome measure was AT recurrence occurring after a 3-month blanking period following the initial ablation procedure. As per current guidelines, AT recurrence was defined 10 as documented AF, atrial flutter or atrial tachycardia lasting ≥30 seconds (2,21).
Pre-specified secondary outcome measures were: quality-of-life 6 and 12 months after initial ablation; time to first AT recurrence; AT burden during the primary outcome period; re-initiation of anti-arrhythmic medication; and comparison of major complication rates.
Procedure-related complications consisted of cardiac tamponade, stroke/transient ischemic 15 attack, myocardial infarction, severe PV stenosis, phrenic nerve paralysis, esophageal perforation or atrio-esophageal fistula, major vascular complications, and death. Definitions were as per international guidelines (2).
Sample size:
A formal sample size calculation was performed assuming a twelve month single-procedure 20 success rate of 64% in the SC group, based on the ThermoCool AF trial results (22), and 90% in the RS group. Although difficult to predict due to the novel trial design, the estimated success rate in the RS group was based on the A4 study, in which up to two additional procedures were allowed within a 90-day blanking period for patients with early recurrence, resulting in 89% freedom from AF at 12 months after a mean of 1.8±0.8 procedures (23) .
Using an alpha error of 0.05 and a beta of 20% (80% power), the number of patients required was 76 (38 in each group). Allowing for 5% attrition gave a total sample size of 80. The study was intentionally underpowered to detect a difference between groups of <25% as it was felt that the magnitude of the additional intervention required a clear and considerable 5 reduction in AT recurrence to be considered acceptable in clinical practice.
Statistical analysis:
All endpoints were examined by means of an intention-to-treat analysis. Categorical variables and endpoints (including the primary endpoint) were summarized as counts (percentages) and compared with χ 2 or Fisher's exact test as appropriate. Continuous variables were checked for 10 normality by visual inspection of the relevant histogram. Where normality was an unreasonable assumption, transformations of the data were attempted (e.g. log and exponential). Continuous variables that were normally distributed were expressed as means (±standard deviation) and were compared using Student's t-tests. Variables that were not normally distributed despite transformation were expressed as medians (interquartile range) 15 and were compared using Mann-Whitney U tests. Time to first AT recurrence was assessed via Cox's Proportional Hazard model, and a comparison was made between groups using the log-rank test. All tests were two-sided and a P-value <0.05 was considered statistically significant.
RESULTS:
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Study participants:
A CONSORT diagram showing recruitment to the study is shown in Figure 2 . Patient demographics for the 80 subjects randomized in the study are provided in Table 1 . The median CHADS-VASc score was higher in the SC group, though this will have been influenced in part by the higher proportion of females in this group. There were no other statistically significant differences between groups at baseline.
Initial procedural characteristics:
There were no significant differences in procedural characteristics between groups (Table 2) .
In 2 patients, the right inferior PV could not be safely isolated at the posterior aspect due to and P=0.82 respectively). All identified sites of acute reconnection were successfully ablated.
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Repeat study procedural characteristics:
All 40 patients randomized to the RS group had the repeat study performed, at a mean interval of 62±6 days after the initial ablation. Thirty-eight patients were in sinus rhythm at the start of the repeat procedure, with 1 in AF and 1 in atrial flutter. Kaplan Meier curves for the 2 groups including clinical redo procedures for documented AT in SC group patients are shown in Figure 4 . The log-rank P value was no longer significant.
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AT burden during the primary outcome period:
Total group AT burden, defined as the number of patient-days on which AT was documented during the primary outcome period, was markedly lower in the RS than the SC group (91 vs. 
Procedure-related adverse events:
No patient suffered death or stroke during the study. One patient developed cardiac tamponade during the initial procedure; this was successfully drained percutaneously without 5 clinical sequelae. This patient was withdrawn from the study prior to randomization but this complication is included in the overall rate. A further patient developed right phrenic nerve palsy following the initial PVI. This resolved completely during the follow-up period. The overall serious complication rate associated with 81 initial procedures was 2.5%.
None of the 40 repeat procedures in the RC group were associated with any adverse 
AFEQT quality-of-life scores:
Baseline AFEQT scores were not different between groups (RS: 46. 
P=0.02).
AT-related urgent hospital admissions:
Excluding elective admissions for repeat AF ablation in both groups, patients in the SC group had markedly more urgent admissions to hospital relating to AT, either as emergency presentations or for electrical cardioversion (11 vs. 3), with a trend towards significance (P=0.10).
Re-initiation of medication:
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Significantly fewer patients in the RS group had anti-arrhythmic medication, including betablockers and calcium-channel blockers, re-initiated in the primary outcome period for symptomatic clinical recurrence (either on a regular or "pill-in-the-pocket" basis) than in the SC group (4/40 (10%) vs. 13/40 (32.5%), P=0.03).
Early recurrence of AT:
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A planned post-hoc analysis of the relationship between early recurrence of AT and the primary endpoint was performed. As shown in Figure 1 , the first 4 weeks post-ablation was regarded as an absolute blanking period based on previous published data suggesting this to be more reflective of the "true" blanking period (25) . The early recurrence period was prespecified as the period from 4 weeks to the repeat study date (RS group) or end of the 15 blanking period (SC group).
In the SC group, 14 patients had early recurrence, of whom 12 (86%) went on to experience the primary endpoint. This proportion was significantly reduced in the RS group 
P<0.001).
The addition of early recurrence also increased the significance of the randomized group (P=0.005).
DISCUSSION:
Main findings: 5 In this randomized controlled trial, we found that a strategy of re-assessment and ablation of PV reconnection after 2 months, irrespective of symptoms, reduces AT recurrence and burden and improves quality-of-life when compared to current standard care, where repeat procedures are only performed for arrhythmia recurrence after an initial blanking period.
While previous data have suggested the potential benefit of early re-intervention in 10 symptomatic patients (26) , to our knowledge, this is the first study to randomize patients irrespective of symptoms to PV re-assessment and re-intervention.
Freedom from AT:
Our study utilized intensive ECG monitoring, which is recognized to result in higher AT detection rates (27), and stringent arrhythmia duration criteria of ≥30 seconds as per 15 international guidelines for clinical trials (2) . AT recurrence occurred in 42.5% of patients in the SC group, in keeping with single-procedure success rates in other contemporary studies (12, 13) . Comparatively, routine early re-intervention resulted in a success rate of 82.5% with the same degree of intensive monitoring. Previous work that has shown that 10-25% of patients may have non-PV triggers (1, 28, 29) , and we did not attempt to look for or ablate 20 these. It is also possible that further PV reconnection following re-ablation may have contributed to recurrence in some cases. Nevertheless, early re-intervention conferred a highly significant absolute improvement in freedom from AT of 25%.
After including clinical redo procedures performed for documented AT recurrence in SC group patients, there was no longer a significant difference in freedom from AT between groups. However, the study was not powered to detect such a difference and, furthermore, follow-up was very short for those patients who underwent a clinical redo procedure, introducing a discrepancy between follow-up periods for the 2 groups. Perhaps more 5 importantly, definitive treatment (the redo procedure) was significantly delayed in these patients compared to the Repeat Study group (210 vs. 62 days), resulting in more AT burden (with more consequent hospital admissions and cardioversions) and more re-initiation of medication in the intervening period. These factors are likely to explain the significant differences in quality-of-life between groups.
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As previous histological studies in animal models have shown that ablation lesion maturation is complete within 1 week after delivery (30,31), it does not seem likely that there is a significant mechanistic difference between reintervention after 2 months and reintervention at a later stage. It would therefore seem that improvements in outcomes are primarily due to a difference in timing of reintervention, which pre-empts later recurrence.
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Context of our results:
PVI remains the cornerstone of successful AF ablation, with recent studies demonstrating a lack of benefit from additional left atrial ablation even in persistent AF (3, 4) . However, this study and others have shown how infrequently that is achieved with a single procedure (5, 6) .
A very recent study attempting to improve durability of PVI by targeting a high Force-Time
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Integral value still showed a significant rate of late reconnection and additionally reported an increased complication rate (32) .
The relationship between PV reconnection and AF recurrence has been clearly established (7) (8) (9) (10) , and while it has previously been shown that complete durable PVI is not essential in all cases to prevent AT recurrence (33) , nevertheless, the aim for operators at the initial procedure is to deliver exactly this. Furthermore, if a patient's AF is truly PV triggerdriven, the only way to achieve certainty that it will not recur is through complete durable PVI. Additional intervention to make up for the limitations of the initial procedure is therefore a potentially logical adjunct.
5
Implications for clinical practice:
Ideally, it would be possible to identify those patients with PV reconnection to focus reintervention towards those with most to gain from it but, at present, imaging modalities cannot accurately identify PV reconnection (34) . We have therefore tested a strategy of invasive re-assessment for PV reconnection in all patients and, while this has resulted in a 10 clear overall improvement in outcomes, there would be significant health economic implications if this were to be adopted into clinical practice. However, the greatest benefit appears to have been in the sub-set of patients with early AT recurrence beyond 4 weeks within the conventional blanking period. We have previously reported that early recurrence in this time period is strongly associated with PV reconnection (35) , and this and other studies 15 have demonstrated the relationship between such recurrence and post-blanking AT recurrence (25, 36) . Although there were no serious complications associated with elective repeat procedures in this study, we acknowledge that this is a relatively small sample size to detect these, and procedures were undertaken by experienced operators in a high-volume center. It may therefore be that targeting patients with such early recurrence may provide the optimal 20 risk/benefit balance and cost-effectiveness.
LIMITATIONS:
The study has some important limitations. Firstly, the size of the study is small, having been powered to detect only a large absolute difference between groups. This was done deliberately as it was felt that the potential additional risk associated with a routine repeat procedure strategy could only be justified by a major improvement in success rates. However, whilst none of the repeat studies were associated with a complication, the size of this study means our ability to detect rare complications is limited. Secondly, this study assessed pointby-point ablation with radiofrequency energy performed by experienced operators. Its role in 5 patients receiving alternate energy sources such as cryoablation cannot be assumed and it is not possible to say with certainty whether our results would be replicated if performed by less experienced physicians. Thirdly, we used validated hand-held monitors to document AF recurrence, believing these provided the most comprehensive non-invasive rhythm monitoring option. Although patients were asked to provide recordings every day and 10 whenever symptomatic, it is possible that asymptomatic episodes lasting less than 24 hours may have been missed. Furthermore, follow-up was relatively short at 12 months. Finally, it was not possible to blind patients to treatment allocation due to the nature of the study, which
could have influenced quality-of-life scores.
CONCLUSIONS:
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A strategy of routine repeat electrophysiology study to assess for and treat PV reconnection in patients with paroxysmal AF provides significant improvements in freedom from AT recurrence, AT burden, and quality-of-life compared to current standard care. Particular benefit from this strategy was seen in those with early AT recurrence beyond 4 weeks within the conventional blanking period.
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PERSPECTIVES:
Competency in Medical Knowledge: In patients with paroxysmal atrial fibrillation undergoing radiofrequency catheter ablation, routine repeat electrophysiology study after two months to assess for and treat pulmonary vein reconnection provides significant improvements in freedom from atrial tachyarrhythmia recurrence, atrial tachyarrhythmia 5 burden and quality-of-life compared to current standard care. likelihood that all pulmonary veins will remain isolated following the procedure. They should be informed that early re-intervention may be beneficial, especially if they experience early 10 recurrence of atrial tachyarrhythmia beyond four weeks after the initial procedure.
Translational Outlook 1:
As this was a relatively small, single-center study, a larger multicenter study should be undertaken to assess the safety of a strategy of routine reintervention in all patients.
Translational Outlook 2: Particular benefit from routine re-intervention to assess for and 15 treat pulmonary vein reconnection was seen in those patients with early recurrence of atrial tachyarrhythmia in the blanking period beyond four weeks after the initial procedure. Further study of focusing this strategy on these individuals should be undertaken.
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FIGURE LEGENDS:
Figure 1: PRESSURE Study timeline
Graphical representation of blanking and recurrence periods during the study. For both randomization groups, the clinical blanking period (during which recurrence did not contribute to the primary endpoint) was 3 months from the date of the initial ablation. For the 5 purposes of a pre-specified sub-analysis, the first 4 weeks after the initial PVI procedure was categorized as an absolute blanking period, with episodes of AT occurring from this point until 3 months (SC group) or the repeat PVI (RS group) being considered as early recurrence of AT (ERAT). Table 1 : Baseline characteristics of all study participants and by randomization group.
AP -anteroposterior; ACE-I -angiotensin converting enzyme inhibitor; ARB -angiotensin receptor blocker; NOAC -non-Vitamin K oral anticoagulant 
